Advanced search
Publication Cover
Future Oncology Volume 18, 2022 - Issue 17
Submit an article Journal homepage
313
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Real-world outcomes of systemic therapy in locally advanced, recurrent or metastatic cutaneous squamous cell carcinoma

Thao T Vo1 Merck and Co., Inc.,Kenilworth, NJ 07033, USACorrespondence[email protected]
View further author information
,
Janet L Espirito2 Ontada,Irving, TX 75039, USAView further author information
,
Marley Boyd2 Ontada,Irving, TX 75039, USAView further author information
,
Burak Gumuscu1 Merck and Co., Inc.,Kenilworth, NJ 07033, USAView further author information
,
Diana Chirovsky1 Merck and Co., Inc.,Kenilworth, NJ 07033, USAView further author information
,
Nicholas J Robert2 Ontada,Irving, TX 75039, USAView further author information
,
Ramona F Swaby3 Prelude Therapeutics,Wilmington, DE 19803, USAView further author information
,
Wei Zhou1 Merck and Co., Inc.,Kenilworth, NJ 07033, USAView further author information
&
Charles Lance Cowey4 Texas Oncology,Dallas, TX 75251, USAORCID Iconhttps://orcid.org/0000-0001-8597-8486View further author information
ORCID Icon show all
Pages 2087-2099 | Received 28 Sep 2021, Accepted 16 Feb 2022, Published online: 04 Mar 2022

References

  • Rogers HW , WeinstockMA, FeldmanSR, ColdironBM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. JAMA Dermatol.151(10), 1081–1086 (2015).
  • Burton KA , AshackKA, KhachemouneA. Cutaneous squamous cell carcinoma: a review of high-risk and metastatic disease. Am. J. Clin. Dermatol.17(5), 491–508 (2016).
  • Karia PS , HanJ, SchmultsCD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J. Am. Acad. Dermatol.68(6), 957–966 (2013).
  • Karia PS . Epidemiology and outcomes of cutaneous squamous cell carcinoma. In: High-Risk Cutaneous Squamous Cell Carcinoma.Springer-Verlag, Heidelberg, Germany (2016).
  • National Comprehensive Cancer Network . Clinical practice guidelines in oncology: squamous cell skin cancer. Version 2 (2021). www.nccn.org/professionals/physician_gls/pdf/squamous.pdf
  • US FDA . FDA approves cemiplimab-rwlc for metastatic or locally advanced cutaneous squamous cell carcinoma (2019). www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-cemiplimab-rwlc-metastatic-or-locally-advanced-cutaneous-squamous-cell-carcinoma
  • Migden MR , RischinD, SchmultsCDet al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N. Engl. J. Med.379(4), 341–351 (2018).
  • US FDA . FDA approves pembrolizumab for cutaneous squamous cell carcinoma (2020). www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-cutaneous-squamous-cell-carcinoma
  • Grob JJ , GonzalezR, Basset-SeguinNet al. Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629). J. Clin. Oncol.38(25), 2916–2925 (2020).
  • Eisenhauer EA , TherasseP, BogaertsJet al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer45(2), 228–247 (2009).
  • Ma X , BellomoL, MageeKet al. Characterization of a real-world response variable and comparison with RECIST-based response rates from clinical trials in advanced NSCLC. Adv. Ther.38(4), 1843–1859 (2021).
  • The US Oncology Network. Empowering local cancer care(2022). www.usoncology.com/our-company
  • Khozin S , MiksadRA, AdamiJet al. Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer. Cancer125(22), 4019–4032 (2019).
  • Feinberg BA , BharmalM, KlinkAJ, NabhanC, PhatakH. Using Response Evaluation Criteria in Solid Tumors in real-world evidence cancer research. Future Oncol.14(27), 2841–2848 (2018).
  • Friends of Cancer Research . Establishing a framework to evaluate real-world endpoints (2018). https://friendsofcancerresearch.org/publications/establishing-framework-evaluate-real-world-endpoints
  • Hillen U , LeiterU, HaaseSet al. Advanced cutaneous squamous cell carcinoma: a retrospective analysis of patient profiles and treatment patterns – results of a non-interventional study of the DeCOG. Eur. J. Cancer96, 34–43 (2018).
  • JarkowskiA3rd , HareR, LoudPet al. Systemic therapy in advanced cutaneous squamous cell carcinoma (CSCC): the Roswell Park experience and a review of the literature. Am. J. Clin. Oncol.39(6), 545–548 (2016).
  • Maubec E , PetrowP, Scheer-SenyarichIet al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J. Clin. Oncol.29(25), 3419–3426 (2011).
  • Cowey CL , RobertNJ, EspiritoJLet al. Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy. Cancer Med.9(20), 7381–7387 (2020).
  • Walker B , BoydM, AguilarKet al. Comparisons of real-world time-to-event end points in oncology research. JCO Clin. Cancer Inform.5, 45–46 (2021).
  • Huang Bartlett C , MardekianJ, CotterMJet al. Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer. PLoS ONE15(4), e0227256 (2020).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.